Current Gastroenterology Reports

, Volume 4, Issue 6, pp 463–470 | Cite as

Gastric neoplasia

  • Pelayo Correa

Abstract

This review summarizes the significant recent advances in our understanding of the clinical, epidemiologic, and pathologic aspects of gastric adenocarcinoma, gastrointestinal stromal tumors (GISTs), and mucosa-associated lymphoid tissue (MALT) lymphoma. Most of the advances in distal gastric adenocarcinoma are in its etiology and pathogenesis. The modulation of the inflammatory response to Helicobacter pylori organisms has been determined to be at the center of the precancerous process. These advances in the understanding of the pathogenesis of H. pylori-related carcinogenesis are relevant to the design of prevention strategies in high-risk populations. New markers of GISTs have focused on the cell of origin and have made possible the development and monitoring of new drugs that are effective even in metastatic tumors. MALT lymphomas have been causally associated with H. pylori infection. Molecular markers are useful to distinguish tumors that respond to H. pylori eradication from those requiring classic chemotherapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: Of importance Of major importance

  1. 1.
    El-Serag HB: Epidemiological differences between adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia. Gut 2002, 50:368–372.PubMedCrossRefGoogle Scholar
  2. 2.
    Blot W, Devesa SS, Kneller W, et al.: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287–1289.PubMedCrossRefGoogle Scholar
  3. 3.
    Pisani P, Parkin DM, Bray F, et al.: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999, 83:18–29.PubMedCrossRefGoogle Scholar
  4. 4.
    International Agency for Research on Cancer: Schistosomes, liver flukes and Helicobacter pylori. In World Health Organization IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 61. Lyon, France: IARC; 1994.Google Scholar
  5. 5.
    Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784–789. An interesting follow-up report on patients infected with H. pylori, including several clinical and histopathologic diagnoses.PubMedCrossRefGoogle Scholar
  6. 6.
    Falush D, Kraft C, Taylor NS, et al.: Recombination and mutation during long-term gastric colonization by Helicobacter pylori: estimates of clock rates, recombination size, and minimal age. Proc Natl Acad Sci U S A 2001, 98:15056–15061.PubMedCrossRefGoogle Scholar
  7. 7.
    Censini S, Lange C, Xiang Z, et al.: cag, a Pathogenicitiy island of Helicobacter pylori, encodes type I-specific and diseaseassociated virulence factors. Proc Natl Acad Sci U S A 1996, 93:14648–14653.PubMedCrossRefGoogle Scholar
  8. 8.
    Blaser MJ, Perez-Perez G, Kleanthous H, et al.: Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995, 55:2111–2115.PubMedGoogle Scholar
  9. 9.
    Parsonnet J, Friedman G, Orentreich N, et al.: Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997, 40:297–301.PubMedGoogle Scholar
  10. 10.
    Covacci A, Telford J, Del Guidice G, et al.: Helicobacter pylori virulence and genetic geography. Science 1999, 284:1328–1333.PubMedCrossRefGoogle Scholar
  11. 11.
    Higashi H, Tsutsumi R, Muto S, et al.: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori Cag A protein. Science 2002, 295:683–686.PubMedCrossRefGoogle Scholar
  12. 12.
    Van Doorn LJ, Figuieredo C, Sanna R, et al.: Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology 1999, 116:823–830. The authors provide extensive genotyping of strains from many countries.PubMedCrossRefGoogle Scholar
  13. 13.
    Figuereido C, Machado JC, Pharoa P, et al.: Helicobacter pylori and interleukin-1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst, in press.Google Scholar
  14. 14.
    Ekstrom AM, Held M, Hansson LE, et al.: Helicobacter pylori in Gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001, 121:784–791. Serology study that strengthens the association between H. pylori infection and gastric cancer.PubMedCrossRefGoogle Scholar
  15. 15.
    El-Omar E, Carrington M, Chow WH, et al.: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398–402. Seminal paper on genetic susceptibility.PubMedCrossRefGoogle Scholar
  16. 16.
    Magnusson PK, Enroth H, Eriksson I, et al.: Gastric cancer and human leukocyte antigen: distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori. Cancer Res 2001, 61:2684–2689.PubMedGoogle Scholar
  17. 17.
    Gendler SJ: Muc1: the Renaissance molecule. J Mammary Gland Biol Neoplasia 2001, 6:339–353.PubMedCrossRefGoogle Scholar
  18. 18.
    Carvalho F, Peixoto A, Steffensen R, et al.: MUC1 gene polymorphism does not explain the differenct incidence of gastric cancer in Portugal and Denmark. Ann Hum Genet 1999, 63:187–191.PubMedCrossRefGoogle Scholar
  19. 19.
    Mohammadi M, Czinn S, Redline R, et al.: Helicobacter-specific cell-mediated immune response display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomach of mice. J Immunol 1996, 156:4729–4738.PubMedGoogle Scholar
  20. 20.
    Nedrud J, Mohammadi M, Blanchard T, et al.: Th1/Th2 lymphocyte response in Helicobacter infections. Helicobacter pylori 1998, 101–109.Google Scholar
  21. 21.
    Fox J, Beck P, Dangler C, et al.: Concurrent enteric helminth infection modulates inflammation and gastric immune response and reduces Helicobacter-induced gastric atrophy. Nat Med 2000, 6:536–542.PubMedCrossRefGoogle Scholar
  22. 22.
    Torres J, Perez-Perez G, Goodman K, et al.: A comprehensive review of the natural history of Helicobacter pylori infection in children. Arch Med Res (Mexico) 2000, 31:431–469. An excellent and informative review of the infection in children.CrossRefGoogle Scholar
  23. 23.
    Goodman K, Correa P: Transmission of Helicobacter pylori among siblings. Lancet 2000, 335:332–333, 358–362. Population-based studies of transmission pathways in a high-risk population.Google Scholar
  24. 24.
    Blaser MJ, Chyou P, Nomura A: Age at establishment of Helicobacter pylori infection and gastric carcioma, gastric ulcer, and duodenal ulcer risk. Cancer Res 1995, 55:562–565.PubMedGoogle Scholar
  25. 25.
    Correa P, Fontham ETH, Bravo JC, et al.: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000, 92:730–735.CrossRefGoogle Scholar
  26. 26.
    Chun B, Wong Y, Lam SK, et al.: Eradication of Helicobacter pylori infection significantly slows progression of precancerous lesions in high risk population: a 5 year prospective randomized study [abstract]. Gastroenterology 2002, 122:A588.Google Scholar
  27. 27.
    Martin JF, Bazin P, Feroldi J, et al.: Tumerus myoides intramurales de l’estomac: consideration microscopiques a propose de 6 cas. Ann Anat Path 1960, 5:484–497.Google Scholar
  28. 28.
    Stout AP: Bizarre smooth muscle tumors of the stomach. Cancer 1962, 15:400–409.PubMedCrossRefGoogle Scholar
  29. 29.
    Mazur MT, Clark HB: Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983, 7:507–519.PubMedCrossRefGoogle Scholar
  30. 30.
    Miettinen M, Virolainen M, Sarlomo-Rikala M: Gastrointestinal stromal tumors: value of CD 34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995, 19:207–216.PubMedCrossRefGoogle Scholar
  31. 31.
    Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577–580. Seminal work describing the molecular abnormalities in the c-kit gene in GISTs. It provides the background and rationale for tyrosine kinase functions and abnormalities and their relevance to GISTs and interstitial cells of Cajal.PubMedCrossRefGoogle Scholar
  32. 32.
    Kindblom LG, Remotti HE, Aldenborg F, et al.: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cell of Cajal. Am J Pathol 1996, 152:1259–1269. A thorough evaluation of immunohistochemical markers in 78 GISTs. The authors report on CD34 and c-kit as markers of GIST and make the connection with interstitial cells of Cajal.Google Scholar
  33. 33.
    Thuneberg L: Interstitial cells of Cajal: intestinal pacemaker cells? In Advances in Anatomy: Embryology and Cell Biology. Edited by Beck F, Hild W, van Limborgh J, et al. Berlin: Springer Verlag; 1982:1–130.Google Scholar
  34. 34.
    Barajas-L’opez C, Berezin I, Daniel EE, et al.: Pacemaker activity recorded in interstitial cells of Cajal of the gastrointestinal tract. Am J Physiol 1989, 257:C830-C835.Google Scholar
  35. 35.
    Robinson TL, Sircas K, Hewlett BR, et al.: Gastrointestional stromal tumors originate from a subset of CD 34 positive interstitial cells with Cajal. Am J Pathol 2000, 156:1156–1163.Google Scholar
  36. 36.
    Spritz RA, Strunk KM, Lee ST, et al.: A YAC contig spanning a cluster of human type III receptor protein kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 1994, 15:431–436.CrossRefGoogle Scholar
  37. 37.
    Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors: recent advance in understanding of their biology. Hum Pathol 1999, 30:1213–1220. The authors review the chemical and histopathologic aspects of GISTs in this well-illustrated, well-written article. They compare GISTs with other nonepithelial tumors, including gastic autonomic nerve tumors, schwannomas, and leiomyomas.PubMedCrossRefGoogle Scholar
  38. 38.
    Beghini A, Tibiletti MG, Roversi G, et al.: Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001, 92:657–662. Report on a family with the dominantly inherited trait of hyperpigmented skin spots, multiple GISTs, diffuse hyperplasia of the myenteric plexus, and urticaria pigmentosa. An immunohistochemical evaluation of CD117 and CD34 is included.PubMedCrossRefGoogle Scholar
  39. 39.
    Berman J, O’Leary TJ: Gastrointestinal stromal tumor workshop. Hum Pathol 2001, 32:578–582.PubMedCrossRefGoogle Scholar
  40. 40.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effects of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1502–1056. The first report on the effective treatment of multiple GISTs with STI-571. It includes good clinical and histopathologic illustrations.CrossRefGoogle Scholar
  41. 41.
    Jacobs DS: Primary gastric malignant lymphoma and pseudolymphoma. Am J Clin Pathol 1963, 40:379–394.PubMedGoogle Scholar
  42. 42.
    Wyatt JJ, Rathbone BJ: Immune response of the gastric mucosa to camplyobactor pylori. Scand J Gastroenterol 1988, 23:44–49.Google Scholar
  43. 43.
    Genta RM, Hammer HW, Graham DY: Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution and response to triple therapy. Hum Pathol 1993, 24:577–583.PubMedCrossRefGoogle Scholar
  44. 44.
    Nomura A, Stemmermann GN, Chyou MH, et al.: Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991, 325:1132–1136.PubMedCrossRefGoogle Scholar
  45. 45.
    Parsonnet J, Friedman GD, Vandersteen DB: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991, 325:1127–1131.PubMedCrossRefGoogle Scholar
  46. 46.
    Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al.: Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991, 338:1175–1176.PubMedCrossRefGoogle Scholar
  47. 47.
    Issacson P, Spencer J: Is gastric lymphoma an infectious disease? Hum Pathol 1993, 24:569–570.CrossRefGoogle Scholar
  48. 48.
    Starostik P, Patzenr J, Greiner A, et al.: Gastric marginal zone Bcell lymphomas of MALT type develop along two distinct pathogenetic pathways. Blood 2002, 99:301–509.CrossRefGoogle Scholar
  49. 49.
    Wotherspoon AC, Dogan A, Du MQ: Mucosa-associated lymphoid tissue lymphoma. Curr Opin Hematol 2002, 9:50–55.PubMedCrossRefGoogle Scholar
  50. 50.
    Montalban C, Santon A, Boixeda D, et al.: Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication: long-term results after sequential histologic and molecular follow-up. Haematologica 2001, 86:609–617.PubMedGoogle Scholar

Copyright information

© Current Science Inc. 2002

Authors and Affiliations

  • Pelayo Correa
    • 1
  1. 1.Department of PathologyLouisiana State University Health Sciences CenterNew OrleansUSA

Personalised recommendations